FEATURES OF ANTIAGGREGATORY AND ANTI-INFLAMMATIORY EFFICACY OF ACETYLSALICYLIC ACID IN PATIENTS WITH CORONARY HEART DISEASE

Аннотация

Despite advances in medical science and prevention, cardiovascular pathology remains the leading cause of morbidity and mortality in economically developed countries. Acetylsalicylic acid (ASA) is currently the most widely prescribed and most proven base drug for oral antiaggregant therapy in cardiovascular disease. Despite the widespread use of acetylsalicylic acid to prevent cardiovascular complications in patients with ischemic heart disease (IHD) ischemic events also occur in a certain proportion of patients receiving regular antithrombotic therapy, which is associated with stagnation of ASA, that is seen as a manifestation of resistance. The problem of resistance to antiplatelet drugs is fundamental in its importance, as it lays the groundwork for the individualization of preventive therapy and the formation of more effective methods of disease prevention. This article discusses the problems that arise in the antiaggregant and anti-inflammatory effect of acetylsalicylic acid in the use of ischemic heart disease.